Main Category: Prostate / Prostate Cancer
Article Date: 26 Dec 2012 – 0:00 PST
email to a friend printer friendly opinions
<!– rate article
Patient / Public:
Researchers at Mayo Clinic’s campus in Florida have identified an enzyme specifically linked to aggressive prostate cancer, and have also developed a compound that inhibits the ability of this molecule to promote the metastatic spread of the cancer.
Their study, published in the Dec. 18 online edition of Molecular Cancer Research, is the first to link the enzyme PRSS3 to prostate cancer.
“This molecule is a protease, which means it digests other molecules. Our data suggests PRSS3 activity changes the environment around prostate cancer cells – perhaps by freeing them from surrounding tissue – to promote malignancy and invasiveness,” says the study’s senior investigator, Evette Radisky, Ph.D., a cancer biologist in the Mayo Clinic Cancer Center. “I don’t think PRSS3 is the only factor involved in driving aggressive prostate cancer, but it may be significant for a certain subset of this cancer – the kind that is potentially lethal,” she says.
Dr. Radisky and five colleagues at Mayo Clinic in Florida made the discovery by investigating publicly available databases, derived from clinical studies, which contain data on molecules
Read more at: http://www.medicalnewstoday.com/releases/254283.php